Comerica Bank increased its position in Cynosure, Inc. (NASDAQ:CYNO) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,823 shares of the medical equipment provider’s stock after buying an additional 1,467 shares during the period. Comerica Bank owned about 0.11% of Cynosure worth $1,139,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of CYNO. 1st Global Advisors Inc. purchased a new position in shares of Cynosure during the third quarter valued at approximately $642,000. Acadian Asset Management LLC purchased a new position in shares of Cynosure during the third quarter valued at approximately $658,000. Nationwide Fund Advisors increased its position in shares of Cynosure by 16.5% in the third quarter. Nationwide Fund Advisors now owns 85,519 shares of the medical equipment provider’s stock valued at $4,356,000 after buying an additional 12,130 shares during the period. Lebenthal Lisanti Capital Growth LLC increased its position in shares of Cynosure by 4.6% in the third quarter. Lebenthal Lisanti Capital Growth LLC now owns 14,807 shares of the medical equipment provider’s stock valued at $754,000 after buying an additional 645 shares during the period. Finally, American Capital Management Inc. purchased a new position in shares of Cynosure during the third quarter valued at approximately $4,080,000.
Cynosure, Inc. (NASDAQ:CYNO) remained flat at $66.00 on Friday. The firm’s 50 day moving average price is $62.47 and its 200-day moving average price is $50.89. Cynosure, Inc. has a 12-month low of $39.90 and a 12-month high of $66.65.
Cynosure (NASDAQ:CYNO) last announced its quarterly earnings data on Tuesday, February 7th. The medical equipment provider reported $0.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.03. Cynosure had a net margin of 3.56% and a return on equity of 6.86%. The firm earned $122.10 million during the quarter, compared to analyst estimates of $119.97 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Cynosure’s quarterly revenue was up 19.2% on a year-over-year basis. Analysts predict that Cynosure, Inc. will post $1.59 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Cynosure, Inc. (CYNO) Position Increased by Comerica Bank” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/04/21/cynosure-inc-cyno-stake-boosted-by-comerica-bank-updated-updated.html.
Several brokerages recently issued reports on CYNO. Northcoast Research cut shares of Cynosure from a “buy” rating to a “sell” rating and set a $40.00 price target on the stock. in a research report on Friday, January 6th. TheStreet upgraded shares of Cynosure from a “hold” rating to a “buy” rating in a research report on Wednesday, January 4th. Northland Securities set a $60.00 price target on shares of Cynosure and gave the company a “buy” rating in a research report on Monday, January 23rd. Zacks Investment Research cut shares of Cynosure from a “hold” rating to a “sell” rating in a research report on Monday, January 9th. Finally, Aegis restated a “buy” rating and issued a $60.00 price objective on shares of Cynosure in a report on Tuesday, January 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $58.63.
Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.
What are top analysts saying about Cynosure Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cynosure Inc. and related companies.